Global Glioblastoma Multiforme Treatment Market to Reach US$ 3.9 Billion by 2032, Propelled by Rising Incidence of Glioblastoma Multiforme

April 17, 2023 | Healthcare

According to the latest report by IMARC Group, titled “Glioblastoma Multiforme Treatment Market Report by Drug Type (Temozolomide, Bevacizumab, Carmustine, Radiosensitizers, and Others), Route of Administration (Oral, Parenteral), Type of Molecule (Small Molecule, Biologics), Distribution Channel (Hospitals, Pharmacies, and Others), and Region 2024-2032," the global glioblastoma multiforme treatment market size reached US$ 2.1 Billion in 2023. Glioblastoma multiforme (GBM) refers to an aggressive and malignant brain tumor that arises from the supportive tissues of the brain. Its symptoms include nausea, headache, vomiting, seizures, weakness, difficulty speaking, cognitive decline, personality changes, and motor deficits. It is diagnosed through neurological examinations, cognitive assessments, biopsy, and various imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans. GBM treatment involves medications, surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. These treatments prevent tumor growth, kill cancer cells, slow disease progression, stimulate the immune system, and alleviate various symptoms. They also aid in improving clinical outcomes, increasing survival rates, regaining lost motor functions, and enhancing patients’ quality of life. 

Global Glioblastoma Multiforme Treatment Market Trends:

The rising incidence of GBM due to inherited genetic conditions, radiation exposure, and environmental factors is one of the primary factors creating a positive outlook for the market. GBM treatments are widely used to slow down the progression of the disease, prevent tumor growth, kill cancer cells, increase patients’ survival rate, and manage various symptoms, such as headaches, seizures, and neurological deficits. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of GBM to improve clinical outcomes, prevent future complications, reduce healthcare expenditure, and enhance patients’ quality of life is providing an impetus to the market growth. Additionally, the recent development of tumor treating fields (TTF) therapy, which is a non-invasive treatment that utilizes electrical fields to disrupt cell division and slow down cancer progression, is positively influencing the market growth. Apart from this, the integration of artificial intelligence (AI)-based algorithms to improve the accuracy of diagnosis, identify the best treatment plan, predict patient outcomes, and aid clinicians in making informed decisions is providing a thrust to the market growth. Moreover, the implementation of various government initiatives to improve healthcare infrastructure and provide access to high-quality treatment options is facilitating the market growth. Other factors, including rising healthcare expenditure, increasing investment in the research and development (R&D) of advanced treatments, and the growing numbers of drug approval, are anticipated to drive the market growth. On account of the aforementioned factors, the market value is expected to reach US$ 3.9 Billion by 2032, exhibiting a CAGR of 6.7% during 2024-2032. 

Market Summary:

  • On the basis of the drug type, the market has been divided into temozolomide, bevacizumab, carmustine, radiosensitizer, and others.
  • Based on the route of administration, the market has been bifurcated into oral and parenteral.
  • On the basis of the type of molecule, the market has been classified into small molecule and biologics.
  • Based on the distribution channel, the market has been divided into hospitals, pharmacies, and others.
  • On a regional basis, the market has been categorized into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
  • The competitive landscape of the industry has also been examined, with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.

Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Drug Type, Route of Administration, Type of Molecule, Distribution Channel, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Glioblastoma Multiforme Treatment Market to Reach US$ 3.9 Billion by 2032, Propelled by Rising Incidence of Glioblastoma Multiforme
Purchase options

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us

Phone: +1-631-791-1145


Phone: +91-120-433-0800


Phone: +44-753-714-6104


Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More